Methotrexat (Methotrexate Disodium)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for producing tetrahydrofolate. This limits the synthesis of nucleotides needed for DNA, RNA, and protein formation, thereby reducing the proliferation of immune cells and cancer cells.

The specific dose of Methotrexat is determined by the prescribing clinician based on the patient’s condition, weight, renal and hepatic function, and treatment protocol. Dosage regimens vary widely between autoimmune indications and oncologic protocols.

Methotrexat is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations and miscarriage. It is also not recommended while breastfeeding because it can be excreted in milk and harm the infant.

To order Methotrexat, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Compared with biologic agents for rheumatoid arthritis or psoriasis, methotrexate is a small‑molecule drug that is generally less expensive but may require more laboratory monitoring. In oncology, it is often used in combination chemotherapy regimens, offering a different mechanism of action than taxanes or anthracyclines.

Methotrexat should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The product should be kept in its original packaging until use to maintain stability and sterility.

Methotrexat is supplied as a sterile injectable solution and can be given by intramuscular, intravenous, or intrathecal injection, depending on the indication and prescribing protocol. Administration is performed by qualified healthcare professionals in a clinical setting.

Serious risks include severe liver toxicity, pulmonary fibrosis, bone‑marrow failure leading to pancytopenia, and acute renal failure. Patients should be monitored regularly for signs of organ dysfunction, and any severe adverse events require immediate medical attention.

Methotrexat is contraindicated in pregnant women, patients with severe hepatic or renal impairment, those with existing bone‑marrow suppression, and individuals receiving live vaccines. It should also be avoided in patients with known hypersensitivity to methotrexate or any component of the formulation.